Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023).
Saved in:
| Title: | Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023). |
|---|---|
| Authors: | Iannantuono, Giovanni Maria1 (AUTHOR), Floudas, Charalampos S.2 (AUTHOR), Filetti, Marco1 (AUTHOR), Giovagnoli, Tommaso1 (AUTHOR), Sganga, Stefano3,4 (AUTHOR), Vitale, Antonio3,4 (AUTHOR), Chandran, Elias5 (AUTHOR), Lombardi, Pasquale1,6 (AUTHOR), Rosenfeld, Roberto7 (AUTHOR), Giudice, Elena8 (AUTHOR), Xue, Elisabetta2 (AUTHOR), Rapisarda, Elvira9 (AUTHOR), Troisi, Paola3,4 (AUTHOR), Apolo, Andrea B.5 (AUTHOR), Karzai, Fatima5 (AUTHOR), Bria, Emilio3,10 (AUTHOR), Gulley, James L.2 (AUTHOR), Daniele, Gennaro1 (AUTHOR) gennaro.daniele@policlinicogemelli.it |
| Source: | European Journal of Cancer. Jul2025, Vol. 225, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
